Filing Flows › Apyx Medical (APYX) › Q3 2026 › vs Q2 2026
Apyx Medical (APYX) Q3 2026 vs Q2 2026 (quarter over quarter)
Apyx Medical's revenue rose $146K (+1%) from $13.9M in Q2 2026 to $14.0M in Q3 2026.
Apyx Medical, Q3 2026: revenue $14.0M (+9% year over year), operating margin -4.1%, net loss $1.8M, operating cash flow −$1.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $14.0M | $13.9M | $146K | +1% |
| Net loss | $1.8M | $3.1M | −$1.3M | -41% |
| Costs & expenses | $15.8M | $17.0M | −$1.1M | -7% |
| Operating costs | $14.6M | $15.7M | −$1.1M | -7% |
| Interest & other, net | $1.1M | $1.1M | −$23K | -2% |
| Income tax | $116K | $124K | −$8K | -6% |
| Cost of revenue | $5.0M | $5.0M | $15K | +0.3% |
| Research & development | $849K | $793K | $56K | +7% |
| SG&A | $4.0M | $5.3M | −$1.3M | -25% |
| Other operating costs | $4.7M | $4.6M | $145K | +3% |
| Operating cash sources | $2.6M | $4.8M | −$2.2M | -46% |
| Depreciation & amortization | $187K | $196K | −$9K | -5% |
| Share-based compensation | $753K | $1.1M | −$321K | -30% |
| Cash used in operations | $1.6M | $3.5M | −$1.9M | -53% |
| Net loss absorbed | $1.8M | $3.1M | −$1.3M | -41% |
| Working capital & other | $768K | $1.7M | −$920K | -55% |
Questions
How much did Apyx Medical's revenue grow quarter over quarter in Q3 2026?
Apyx Medical's revenue rose $146K (+1%) from $13.9M in Q2 2026 to $14.0M in Q3 2026.